DUBLIN & BURLINGAME, Calif.--(BUSINESS WIRE)--ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that ALX148 clinical results have been selected for presentation in the Poster Discussion Session at the 2019 ASCO Annual Meeting, May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.
ALX148 Presentation Information
Title: A phase 1 study of ALX148, a CD47 blocker, in combination
with established anticancer antibodies in patients with advanced
malignancy (Abstract #2514).
Poster Discussion Session: Developmental Immunotherapy and Tumor Immunobiology, Advances in Immune Checkpoint Inhibition
Date: Saturday, June 1
Time: 1:15 p.m. – 1:27 p.m.
Location: Hall D1
Poster Display Session: Developmental Immunotherapy and Tumor Immunobiology
Date: Saturday, June 1
Time: 8:00 a.m. – 11:00 a.m.
Location: Hall A
About ALX Oncology
ALX Oncology is a clinical-stage
immuno-oncology company developing therapies that block the CD47
checkpoint mechanism, which is exploited by cancer cells to evade the
immune system. Our lead candidate, ALX148, is a fusion protein comprised
of an engineered high affinity CD47 binding domain of SIRPα linked to an
inactive Fc region of human immunoglobulin. ALX148 is designed to
maximize the clinical benefit of antibody-based therapies and is in
clinical development for a broad range of tumor types. www.alxoncology.com